An unusual news today: Alchemab Therapeutics, a UK biopharmaceutical company, announced it has entered a collaboration with Lilly to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS). There are a few similar announcements, so it means that Lilly knows that Alchemab's drug has a good chance of developing into a commercial drug. A similar partnership in the ALS field was Ionis with Biogen, which at the end provided Tofersen (Qalsody), which helped some ALS patients.

Alchemab's approach is data-oriented. Instead of trying to find molecules that are causative of a disease and to deactivate them, they search individuals with unusually slow rates of disease progression, or at risk of developing a disease but still healthy, to identify antibodies associated with resilience. Such individuals could be patients with years of survival with typically untreatable cancer, very long-lived, healthy individuals without chronic diseases, or patients with susceptibility to neurodegenerative disease that do not progress (it happens). If you want to know more about their methods, here is a link: https://www.mlsb.io/papers_2023/Enhancing_Antibody_Language_Models_with_Structural_Information.pdf

Alchemab believes these antibodies, which are not found in disease progressors, could present therapeutic opportunities. This is complicated reasoning. Why would antibodies be useful in non-transmissible diseases in general? Why not an approach like those of Ionis, which uses ASO to prevent proteins from being produced by the cell in the first place? And this is too simplistic to my taste, but apparently Lilly thinks otherwise. Alchemab deliberately uses agnostic approaches because it is not tainted by bias or misunderstanding of underlying biology.

Once data-driven approaches find an antibody candidate, it must be modified to be stable and safe for the host. Then it must be tested in pre-clinical studies on animal models, and if successful, in clinical trials involving humans.

Alchemab already has several candidate drugs in its pipeline, and there is one for ALS. The drug is named ATLX-1282, and it targets the protein UNC5C. This protein belongs to the UNC-5 family of netrin receptors. The UNC-5 family of receptors mediate the repellent response to netrin. Netrins are secreted proteins that direct axon extension and cell migration during neural development. They are bifunctional proteins that act as attractants for some cell types and as repellents for others, and these opposite actions are thought to be mediated by two classes of receptors.

So, at least there is some logical connection between the drug and the disease; this is not the case for most drugs (unsuccessfully) tested against ALS. Yet there are thousands of molecules associated with ALS, and it is not disclosed what makes UNC5C a good target in ALS. In addition, netrins apparently act during neural development, yet most ALS patients are at the opposite end of the life span.

Here are some publications on the relation between axon guidance and ALS, but it's not because some scientific publications assert something that it is necessarily true or useful.

https://pubmed.ncbi.nlm.nih.gov/24918638/

https://pubmed.ncbi.nlm.nih.gov/25177267/

https://pmc.ncbi.nlm.nih.gov/articles/PMC2175528/

The only publication I found by Alchemab about ALS and UNC5C is this one: https://www.alchemab.com/wp-content/uploads/2023/12/Society-for-Neuroscience-Posters.pdf I am not sure it proves anything about a link between ALS and UNC5C or even netrins.

Computational analysis links blood RNA patterns to ALS

- Posted by admin in English

Since we still don't know the causes of ALS and several other sporadic neurodegenerative diseases, it's interesting to find potential biomarkers associated with these diseases. Furthermore, since most clinical trials are negative, the pharmaceutical industry is seeking to change the definition of a successful trial by substituting biomarkers for clinical signs, as they are said to be more reliable. While there is some truth in this approach, it still seems highly questionable from an ethical perspective: The sole purpose is to validate clinical trials, even if there is no improvement in patient symptoms.

Researchers are therefore currently working to find biomarkers for neurodegenerative diseases, as the market for these tools appears immense and lucrative. The ideal biomarker would be an inexpensive blood test.

Researchers from Thomas Jefferson University examined two American GEO databases that collect blood samples (plasma and serum). https://www.ncbi.nlm.nih.gov/geo/info/overview.html

The Gene Expression Omnibus (GEO) is a public repository that archives and freely distributes comprehensive microarray, next-generation sequencing, and other forms of high-throughput functional genomics data submitted by the scientific community. These are digital data provided by microbiology tools and are therefore presumed to be reliable, but the associated metadata (provided by humans) may not be of high quality. Furthermore, some datasets submitted to GEO may have been contaminated.

Scientists focused on the small RNA fragments present in these samples. They focused on small non-coding RNAs because these molecules are stable and abundant in blood fluids such as plasma and serum.

These molecules were classified as follows:

  • isomiR: slightly altered versions of microRNAs

  • tRF: fragments from transfer RNA

  • rRF: fragments of ribosomal RNA

  • yRF: fragments of another type of RNA, Y RNAs

  • And a residual group, called "not-itrs," for sequences they initially could not categorize.

The scientists found that these small types of RNA do not appear in sufficient quantities in ALS patients as in healthy people.

Some of these differences were related to the patients' survival time, even after taking into account factors such as age, sex, and whether or not they were taking riluzole (a common treatment for ALS).

Interestingly, some "non-itrs" sequences did not match human DNA, but rather the ribosomal DNA of bacteria (Burkholderiales) or fungi. Some of these foreign sequences were also linked to patient survival. This is a worrying claim.

What should we make of these claims of non-human RNA discovery in patients? Initial contamination is a plausible explanation for the detection of small non-human RNAs (sncRNAs), and it is a known concern in studies of low-input samples such as plasma and serum. But this contamination would also be apparent in samples from people without ALS.

The tools used in microbiology use short reads that are algorithmically reassembled. These short reads are likely to match multiple genomes by chance, increasing the risk of false positives during alignment, particularly if the databases are large and noisy. Here too, contamination would be apparent in samples from people without ALS.

Another explanation is that the presence of non-human genomes in humans is completely normal: our skin, mucous membranes, and internal organs harbor an extensive variety of microorganisms. We don't live in a vacuum. What we do know is that these populations of microorganisms respond to the host's health, sometimes with significant variations. For example, it has been shown that in Alzheimer's disease and, more generally, in aging, the dental microbial population is very different from that of healthy people.

So what can we conclude? There's probably no reason to worry; ALS is probably not caused by specific microbes or microscopic fungi. But that doesn't change the fact that we know that certain cyanobacteria cause a disease similar to ALS.

Abnormal protein aggregation within cells is a recurring phenomenon in Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). Current approaches use antibodies to target these aggregates, but this is a rudimentary approach, as little is known about the causes of their formation, or whether they are the cause or consequence of the disease.

Cells are an incredibly crowded environment, and their molecules undergo Brownian motion, which thwarts their biological function. Making the cell less dense and more soluble would certainly alleviate some molecular problems. There are various approaches, including those that use phase transitions.

Recent research sheds surprising light on the dynamic relationship between mitochondrial activity, ATP levels, and neuronal cytoplasmic fluidity, all of which play a critical role in controlling protein aggregation.

The researchers used mouse giant goblet cell cultures to analyze presynaptic viscosity using real-time confocal microscopy. These cells are characterized by large glutamatergic nerve terminals, ideally suited for real-time imaging. Rather than focusing on individual proteins, the team took a holistic approach, using a technique called fluorescence recovery after photobleaching (FRAP) of soluble green fluorescent protein (cGFP) to assess the overall viscosity of the axonal cytosol.

Cytosolic viscosity can reflect the extent of protein aggregation; Greater aggregation means less free diffusion of cGFP, indicating a more "solidified" cytosol.

Synapses are hotspots for mitochondria, which provide the ATP needed for neurotransmission. By labeling active mitochondria and comparing their location to cGFP mobility, the study revealed that regions with greater mitochondrial activity exhibited higher cytosolic fluidity. This suggests a direct link between ATP production and the maintenance of a more soluble and functional presynaptic environment.

To further investigate this, the team inhibited mitochondrial function using FCCP and other mitochondrial blockers. As ATP production decreased, cGFP diffusion decreased sharply, suggesting that the cytosol was becoming more viscous due to protein aggregation. It is important to note that this effect was specific to mitochondrial inhibition: blocking glycolysis had little effect.

Even components of the synaptic release mechanism, such as synaptic vesicles (SVs) and active zones (AZs), exhibited reduced mobility under mitochondrial stress, reinforcing the idea that energy depletion disrupts the fluid phase of the cytoplasm.

To test whether ATP could restore the altered cytosol state, the researchers administered ATP directly to neurons. They found that ATP not only restored cGFP diffusion but also reduced the size and number of protein aggregates. To test whether enhancing endogenous ATP production could mitigate the protein aggregation linked to mitochondrial dysfunction, the researchers turned to NMN, a molecule known to boost NAD⁺ levels and support mitochondrial health.

They treated neurons with NMN and observed the following key outcomes:

Partial restoration of cytoplasmic fluidity: In neurons with compromised mitochondrial activity (such as those derived from PARK2 or TDP-43 mutant patients), NMN treatment significantly improved the diffusion of soluble proteins like cGFP. While not as dramatic as direct ATP infusion, NMN nonetheless reduced cytosolic viscosity.

Reduction in aggregate burden: In both mouse neurons under mitochondrial stress and hiPSC-derived human neurons from neurodegenerative disease patients, NMN treatment lowered the accumulation of insoluble protein aggregates.

Improved ATP levels: NMN supplementation helped increase intracellular ATP concentrations, presumably by enhancing mitochondrial NAD⁺-dependent enzymatic activity, which supports oxidative phosphorylation.

These results suggest that NMN supports the same protective pathway as ATP, but indirectly, by restoring mitochondrial capacity to generate ATP and maintain a more fluid intracellular environment.

The mechanism appears to be biophysical rather than biochemical: ATP acts as a hydrotrope, a molecule that keeps other proteins dissolved and prevents them from forming aggregates.

The researchers then examined whether this principle held true for specific proteins involved in neurodegenerative diseases, including:

  • α-synuclein (mutant SNCA and SNCA-A53T), PARK2 – Parkinson's disease

  • APP, Amyloid, Tau – Alzheimer's disease

  • TDP-43 – ALS

These purified proteins were able to undergo liquid-liquid phase separation (LPS) and form condensates in vitro. ATP was able to dissolve many of these condensates in a concentration-dependent manner, although mutant or misfolded versions (e.g., SNCA-A53T) required higher ATP concentrations to dissolve.

When the aggregates were left to incubate for longer, some (notably SNCA-A53T) began to form protofibrils, elongated, fibril-like structures similar to those observed in real-life pathology. Here again, ATP could reverse this phenomenon, but with reduced efficiency.

Even under crowded conditions (mirrored by the addition of PEG), ATP retained some ability to prevent or dissolve aggregates, although the effect was less potent.

The team then studied neurons derived from Human induced pluripotent stem cells (hiPSCs) from patients with Parkinson's disease (PARK2 mutation) and ALS (TDP-43 mutation). These neurons exhibited reduced cytosolic fluidity, lower ATP levels, and greater protein aggregation than healthy controls.

This supports the idea that ATP deficiency and mitochondrial dysfunction contribute to the condensation of pathogenic proteins in human neurodegenerative diseases.

Implications for Drug Development

This research redefines our approach to therapeutic targets in neurodegenerative diseases. Instead of seeking to eliminate aggregates after their formation, we could:

  • Target mitochondrial function to preserve ATP production at synapses.

  • Use small molecules that mimic the hydrotropic effects of ATP to maintain cytoplasmic fluidity.

  • Develop drugs that prevent the formation of LPS (lipoproteinases) of key disease proteins by improving their solubility.

ATP itself is not a drug molecule in the traditional sense, but these results open new avenues for small molecules capable of acting like ATP to maintain protein solubility or prevent aggregate formation at an early stage.

Conclusion

Neurodegenerative diseases are often viewed from a genetic or protein perspective, but this study provides a biophysical perspective: the physical state of the cytosol itself is crucial. If cells cannot maintain a fluid and soluble environment, primarily due to energy deficiency, aggregation may become inevitable.

This is not just about treating symptoms or even eliminating aggregates afterward. It is about preserving the cellular environment so that neurons can withstand stress and maintain their function. As the field continues to explore how biophysical properties such as viscosity, solubility, and phase separation interact with disease, the role of ATP may prove central, not only as a fuel, but also as a key regulator of neuronal health.

Researchers are currently very interested in finding biomarkers for the early detection of many neurodegenerative diseases. The market for these technologies is likely to be quite large. Detecting weakened cerebral rigidity before the onset of irreversible damage could pave the way for early intervention in Alzheimer's disease and related disorders. This could be achieved using a device that has now become relatively common: MRI. enter image description here The hippocampus, a small, seahorse-shaped structure buried deep within the brain, is best known for its role in memory formation and learning. It is an exceptionally vulnerable structure, with perfusion deficits often observed in diseases related to learning and memory. However, a brain affected by Alzheimer's disease tends to exhibit at least moderate cortical atrophy, including in the precuneus and posterior cingulate gyrus. It should be noted that the posterior cingulate gyrus is adjacent to the hippocampus.

A recent study shows a relationship between blood flow and mechanical stiffness (an MRI concept) of the hippocampus. Researchers sought to understand how these physical properties interact in a healthy brain and what this might reveal about early brain changes in neurodegenerative diseases. The researchers used two advanced MRI techniques—magnetic resonance elastography (MRE) and arterial spin labeling (ASL).

Using these tools, the researchers measured: * Tissue stiffness (the resistance of an area to physical deformation) * Perfusion (blood flow at the tissue level)

Seventeen healthy adults were examined by the researchers at two different MRI intensities (3T and 7T), allowing for a cross-comparison between the two magnetic field strengths. They found that the hippocampus had the highest blood flow among the deep gray matter structures, followed closely by the caudate nucleus and putamen.

A strong positive correlation was observed between blood flow and stiffness in the hippocampus, but not in the caudate nucleus, although both regions are highly vascularized. This indicates that good brain health appears to be linked to good blood flow, manifested by the good stability (stiffness) of the tissue.

In a subgroup of ten subjects, it was found that higher blood flow resulted in larger tissue pulsations, suggesting that the dynamics of blood supply physically influence the hippocampus.

These results suggest a previously underestimated link between the physical characteristics of well-perfused brain tissue and its metabolic needs. This connection is not entirely surprising, as the macroscopic characteristics of tissue depend on the well-being of its constituent cells.

Although not mentioned in the article, one might wonder about the relationship between this mechanical property—rigidity—and beta-amyloid (Aβ), the signature protein implicated in Alzheimer's disease.

Beta-amyloid plaques begin to accumulate in the brain well before the onset of symptoms. These plaques can form: * Extracellularly: outside neurons, interfering with cell-to-cell communication and nutrient supply; * Intracellularly: inside neurons and other nerve cells, disrupting protein production.

Based on current knowledge, beta-amyloid likely appears before physical changes in tissues. It emerges early, sometimes decades before cognitive symptoms, triggering a cascade of tissue changes. Mechanical stiffness, as measured by MRE, is more likely a result of these changes than a cause.

Interestingly, numerous MRE studies have observed brain softening, particularly in the hippocampus and cortex, in Alzheimer's patients and those with mild cognitive impairment. This supports the perspective that stiffness decreases due to beta-amyloid pathology and its effects on brain tissue structure.

As fascinating as these findings are, it is important to acknowledge the limitations of the study, which suggest future research directions.

With only 17 participants, the study lacks statistical power, making it vulnerable to false positives or exaggerated effect sizes.

All subjects were young adults (22–35 years old) who were generally healthy, limiting the relevance of the results to aging populations or those at risk for Alzheimer's disease.

The sample did not include key groups, either clinical or high-risk individuals, such as APOE4 gene carriers or those with mild cognitive impairment (MCI).

The study was cross-sectional, capturing a single snapshot in time. We do not yet know how stiffness or perfusion might change over time or in response to pathology.

No cognitive data were collected; therefore, the relationship between hippocampal mechanics and actual memory performance remains unexplored.

There are considerable interpretation challenges: Stiffness, measured by magnetic resonance elastography (MRE), reflects a complex array of biological factors: neuronal density, inflammation, vascular integrity, etc. It is a valuable signal, but not biologically specific. Indeed, perfusion can vary depending on common physiological factors (e.g., hydration, stress).

Because the study did not include beta-amyloid PET scans or fluid biomarkers, the link between mechanical findings and Alzheimer's pathology remains hypothetical.

The analysis focused on the hippocampus and a few other deep gray matter structures. Key cortical regions involved in Alzheimer's disease (such as the entorhinal cortex or precuneus) were not examined.

The emerging link between perfusion and mechanics, and how this relationship deteriorates in the presence of beta-amyloid, could help us uncover subtle clues that precede cognitive decline. Ultimately, measuring something as simple as brain "firmness" could help us identify those at risk and determine when to act.

Skin pathology in ALS

- Posted by admin in English

Many ALS patients have noticed that their patients seem to share a particular skin type. Studies have shown that ALS patients often exhibit small fiber neuropathy in the skin, contributing to symptoms such as impaired thermoregulation, abnormal sweating, and sensory disturbances (e.g., numbness, and pain). Similar skin changes have been observed in diseases such as Parkinson's disease and Alzheimer's disease, suggesting that skin biomarkers could contribute to the early diagnosis and monitoring of ALS.

The article reviewed here is a review of this phenomenon, which rarely receives scientific attention. While the focus of the article is on early diagnosis of ALS, scientists, and physicians are not necessarily pleased that ALS is a disease far more complex than motor neuron disease, as this makes it difficult to conceptualize and makes the design of therapeutic strategies more challenging.

One factor that may explain this is that the skin and the nervous system share a common embryonic origin. The skin is composed of the epidermis, dermis, subcutaneous tissue, and appendages (such as sweat and sebaceous glands). In patients with ALS, the skin exhibits a soft, leathery texture, as well as a phenomenon called delayed return (DRP). enter image description here In healthy individuals, after a deformation or pinching, the skin quickly returns to its original shape. In patients with ALS, this return is slower. This is called the delayed return phenomenon (DRP).

In the context of ALS, DRP has been associated with abnormalities in the dermal connective tissue, such as altered collagen composition. Microscopic examination reveals fewer and less organized collagen bundles and increasing gaps in the connective tissue. Electron microscopy shows the progressive deposition of fine materials in the dermal matrix, disrupting collagen fibers and connective tissue integrity. These changes reduce the skin's resilience and elasticity, making it softer and slower to regenerate.

ALS patients also exhibit decreased sweat gland nerve fiber density (SGND) and pilomotor nerve fiber density (PNF).

Histological studies show thickening of the walls of small dermal blood vessels, particularly in sporadic ALS (sALS). Electron microscopy reveals onion-like structures formed by β-amyloid deposits and basement membrane duplications, reducing the surface area of ​​the vascular bed. This vascular remodeling, particularly in the papillary layer, may be linked to changes in autonomic innervation and contribute to preventing pressure ulcers.

One of the culprits for this state of affairs could be MMP-9, which belongs to the matrix metalloproteinase (MMP) family. Metalloproteinases degrade extracellular matrix components such as collagen. Proteins of the matrix metalloproteinase (MMP) family are involved in the restructuring of the extracellular matrix in processes such as embryonic development, wound healing, learning, and memory, as well as in pathological processes such as asthma, arthritis, intracerebral hemorrhage, and metastases.

Home-Based Tele-tDCS in Amyotrophic Lateral Sclerosis

- Posted by admin in English

A clinical trial (NCT04866771) was conducted at the University of Illinois Chicago to investigate the effects of remotely supervised transcranial direct current stimulation (tele-tDCS) on ALS patients. By enabling patients to undergo treatment in the comfort of their own homes under remote supervision, tele-tDCS promises to minimize travel-related barriers.

Patients were stratified into two groups based on their ALS Functional Rating Scale (ALSFS) score progression rate. The intervention group received 72 sessions of tele-tDCS, while the delayed-start group received 36 sham sessions followed by 36 active sessions. Out of 70 individuals initially screened, 14 (7 males, 7 females) were enrolled but only 10 participants completed the study. The intervention group had full retention, while the delayed-start group had a 57% retention rate.

Assessments were conducted at six-time points: pre-testing (T0), up to three mid-testing sessions (T1), post-testing at 24 weeks (T2), and a follow-up at three months (T3). These evaluations included functional and neurophysiological tests, as well as clinical and scalp integrity checks.

Tele-tDCS was administered three times per week for 24 weeks, with a stimulation dosage of 2 mA for 20 minutes. The devices were preprogrammed to ensure consistency and prevent alterations by participants or caregivers.

All intervention sessions were facilitated via ZoomPHI, allowing the participant and the researcher to see each other throughout the process. A caregiver was required always to be present to start and stop the session as instructed, ensuring safety and proper operation. Training was provided to ensure correct headset placement and operation, and caregivers were required to assist in starting and stopping each session.

A portable tDCS device (Soterix Medical 1X1 tDCS mini-CT Stimulator, NY) was used in this study. This device included a stimulator, a customized head strap for secure placement, and designated positions for active (anodal current over the lower limb motor cortex) and inactive electrodes (cathodal current over the contralateral supraorbital region).

It featured built-in programmable codes, allowing for controlled session-specific settings under the remote supervision of a researcher. The stimulation dosage of 2 mA for 20 min was preprogrammed into the device by research personnel before being provided to participants.

An interim analysis was conducted after six participants completed the study. The study would be halted for review if the mean ALSFS-score difference between groups exceeded two standard deviations. The "two standard deviations" rule is a way to check if the observed difference between groups is improbable. Participants were categorized as slow, intermediate, or fast progressors based on these rates.

ALSFRS-R scores at the beginning did not significantly differ between groups. enter image description here Some people in the intervention group showed an astonishingly slower disease progression compared to the delayed-start group:

From pre-testing to post-testing at 24 weeks the intervention group mean change was 1.7 (only a little degradation in ALSFR), while in the delayed-start group, there was a 13.6 change. However it looks like the situation in the intervention group was not homogeneous at all, there were patients who reacted extremely well to the therapy, while others reacted extremely badly to the therapy.

Statistically results from a group of 14 people mean absolutely nothing, yet ALS is without cure and this result is much better than in any other ALS clinical trial.

As noted by the authors future studies may benefit from incorporating objective biomarkers such as NFL to assess the effects.

An interesting research article was recently published on bioenergetic subgroups in Alzheimer's Disease. The study found a connection between acylcarnitines, bioenergetic age, and Alzheimer's progression. It opens up interesting possibilities for how we might approach brain health from a metabolic perspective as the study suggests brain health to be largely modifiable rather than genetically determined. Focusing on general metabolic health through evidence-based approaches like regular exercise, quality sleep, and dietary patterns that support mitochondrial function could potentially be beneficial. enter image description here The researchers used acylcarnitine profiles from blood samples to identify distinct bioenergetic subgroups in Alzheimer's Disease (AD) patients and evaluate how bioenergetic capacity relates to disease progression. They used data from 1,531 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), and identified several bioenergetic subgroups with significant differences in AD biomarkers, cognitive function, and brain glucose metabolism. These subgroups were primarily determined by modifiable factors (40-60%) related to beta-oxidation function, rather than genetic factors, suggesting potential for intervention.

The researchers developed a "bioenergetic age" metric based on acylcarnitine levels that strongly correlated with AD pathology. Individuals with "younger" bioenergetic ages showed less severe disease markers. Baseline bioenergetic age predicted cognitive decline over time in multiple studies, independent of APOE ε4 status in most cases. Specific genetic variants (SNPs rs17806888 and rs924135) influenced cognitive decline trajectories, but their protective effect appeared limited to individuals with younger bioenergetic ages. A simulated clinical trial showed that individuals with younger bioenergetic ages had significantly better outcomes on multiple clinical measures, with effect sizes comparable to those seen in the lecanemab anti-amyloid antibody trial.

The research suggests that targeting bioenergetic capacity could be a promising intervention approach for AD, particularly for the approximately 30% of individuals with protective genotypes but older bioenergetic ages.

In addition to the usual recommendations (Exercise/physical activity, dietary approaches, sleep optimization, stress reduction) supplementation (with medical supervision) might be an option:

  • L-carnitine/acetyl-L-carnitine - directly involved in fatty acid transport for beta-oxidation
  • Omega-3 fatty acids - support mitochondrial membrane health
  • Coenzyme Q10 - important for mitochondrial energy production

Today there isn't a widely available, inexpensive rapid test specifically for comprehensive acylcarnitine profiling that consumers can easily access. Yet your doctor could order acylcarnitine profiling, though it's not a routine test. Some companies offer more comprehensive metabolic panels that include some acylcarnitine measurements, though these typically cost $300-500+ and aren't widely validated. There's no equivalent to something like a glucose meter or rapid cholesterol test for measuring acylcarnitines at home or in point-of-care settings.

Statin Use and Amyotrophic Lateral Sclerosis Survival

- Posted by admin in English

There are many articles on statins and ALS, and in general the results show that statin use does not influence the progression of ALS.

Statins are commonly used to manage cholesterol levels and reduce the risk of cardiovascular disease, but their safety in amyotrophic lateral sclerosis (ALS) has long been questioned by both patients and their caregivers. Since the mid-1990s, weight loss has been identified as a contributing factor for patients with ALS, leading to a 7.7-fold increased risk of death. Many individuals worry that statins may accelerate the progression of ALS or exacerbate symptoms, and reports from drug monitoring systems suggest a potential link between a diagnosis of ALS and statin use; however, these reports have yet to be validated in epidemiological studies. In contrast, findings from more recent studies indicate that high LDL cholesterol and elevated LDL/high-density lipoprotein ratios occurring well before the onset of ALS may be associated with an increased risk of developing the disease.

A new Norwegian study on this topic confirms that statin use does not impact the progression of ALS.

https://pubmed.ncbi.nlm.nih.gov/40034089/

The researchers analyzed data from four Norwegian health surveys spanning the years from 1972 to 2003. They linked these surveys to national registries to track ALS diagnoses, mortality, and medication use. Specifically, they examined whether statin use before and after an ALS diagnosis influenced survival time.

The researchers included 524 ALS patients in the analysis. They compared statin use before and after diagnosis and adjusted for various factors, including age, sex, smoking status, BMI, cholesterol levels, and use of riluzole (the main ALS drug).

Their work found no association between statin use and ALS survival. Interestingly, 21% of ALS patients stopped taking statins in the year before their diagnosis. This group had a poorer prognosis, perhaps because of worsening general health, but the fact they stopped using statins did not appear to have improved ALS survival.

The study therefore suggests that routinely stopping statins in ALS patients is not necessary. Since statins do not appear to have a negative impact on survival, stopping them solely because of an ALS diagnosis may deprive patients of their cardiovascular benefits.

Two recent studies highlight the complex interplay between metabolic dysregulation and ALS progression.

The first study investigated energy balance and glucose control in TAR DNA-binding protein 43 (TDP-43)Q331K mice, which serve as a model for ALS, during both the early and late symptomatic stages of the disease. It suggests the presence of compensatory mechanisms that regulate glucose metabolism differently in this form of ALS. Thus, targeting metabolic pathways, such as insulin signaling and oxidative stress, could provide new therapeutic approaches for ALS.

The etiology of ALS is complex, involving mechanisms such as neuroinflammation, protein aggregation, and energy metabolism dysfunction. The origin of hypermetabolism in amyotrophic lateral sclerosis remains unknown; however, metabolic perturbations in skeletal muscle may be a determining factor, including an increase in the expression of pyruvate dehydrogenase kinase 4 (PDK4), which plays a central role in regulating the oxidation of glucose.

Both sporadic and familial ALS cases commonly exhibit metabolic disturbances, including weight loss, increased resting energy expenditure, and hypermetabolism, which are associated with poorer disease outcomes. Interestingly, a higher body mass index (BMI) at disease onset is linked to increased survival, and high-calorie, high-fat diets have shown some benefits in ALS patients and mouse models, suggesting that metabolic interventions could influence disease progression.

Insulin resistance has been implicated in the progression of ALS. Some studies indicate that diabetes mellitus increases the risk of ALS, while others suggest that type 2 diabetes may delay the onset of the disease. This discrepancy highlights the need for further research into how energy homeostasis and insulin signaling are affected in ALS. Previous studies on SOD1G93A mice, a model of familial ALS, revealed increased energy expenditure and enhanced glucose uptake through insulin-independent pathways, along with glucagon intolerance.

The discrepancy between studies may stem from differences in tissue-specific glucose uptake, as ALS patients exhibit increased glucose uptake in denervated muscles but decreased uptake in the central nervous system.

Building on these findings, the first study investigated metabolic perturbations in the TDP-43Q331K mouse model, which mimics the neuropathological and metabolic hallmarks of human ALS, including TDP-43 pathology, a common feature in both familial and sporadic ALS.

TDP-43Q331K mice exhibited significantly increased daily energy expenditure (DEE) from the early symptomatic stages of the disease. This hypermetabolism was accompanied by a transient increase in food intake, which helped maintain fat mass initially but was insufficient in later stages, leading to fat mass reduction.

During the later stages of the disease, TDP-43Q331K mice showed improved glucose clearance, independent of insulin. Despite reduced circulating glucagon levels, these mice maintained normal fasting blood glucose levels, suggesting alternative mechanisms for glucose regulation.

Unlike SOD1G93A mice, TDP-43Q331K mice did not exhibit insulin or glucagon intolerance. Insulin sensitivity remained unchanged, and while glucagon levels were reduced, the mice maintained normal blood glucose levels, indicating the involvement of other regulatory mechanisms.

Consistent with other ALS models, TDP-43Q331K mice experienced a reduction in lean mass during both early and late disease stages. Regression analysis confirmed that the increased energy expenditure was independent of changes in body mass.

The TDP-43Q331K mutation drives significant metabolic changes, including hypermetabolism and altered glucose uptake, which are not observed with wild-type TDP-43.

The increased glucose uptake in later disease stages is insulin-independent, highlighting the activation of alternative metabolic pathways in response to the disease.

The ability of TDP-43Q331K mice to maintain fasting blood glucose levels despite reduced glucagon suggests the existence of compensatory mechanisms that regulate glucose metabolism differently in this ALS model.

  • The second study, a phase 2a clinical trial, explored the pharmacodynamic response of trimetazidine, a partial fatty acid oxidation inhibitor, on oxidative stress markers and energy expenditure in amyotrophic lateral sclerosis. This publication highlights how it's difficult and inconclusive to conduct an ALS clinical trial as twenty-one participants received trimetazidine but only 19 completed the treatment period. While trimetazidine is a well known drug, usually well tolerated, the assessment of energy expenditure may have been uncomfortable. While there were 57 adverse events, the conclusion was, as usual, that the drug was well tolerated! enter image description here While the publication recounts that trimetazidine was beneficial for patients (this is not a phase III trial), for me the results section does not show conclusive results. For example, the results improved only during the wash-out period.

The authors tell that the on-treatment period may have been too short, or the sample size too small to detect a disease-relevant change, if one exists. Moreover, in this study, they simply used the approved dose for angina pectoris. Therefore, it remains unclear whether dosing was appropriate and whether a different dose would have resulted in more substantial reductions. Finally, the response in the oxidative stress markers may also be explained by external factors that influence metabolism, such as concomitant medication use and smoking, which cannot be completely ruled out in this uncontrolled study.

While the study was limited by its short duration and lack of a control group, the findings suggest that trimetazidine may help mitigate the hypermetabolic state in ALS and improve disease outcomes. Larger, randomized controlled trials are needed to confirm these results and determine the optimal dosing regimen.

These findings suggest that targeting metabolic pathways, such as insulin signaling and oxidative stress, could offer new therapeutic avenues for ALS. Future research should focus on understanding the underlying mechanisms of metabolic dysregulation, exploring the potential of antidiabetic agents, and conducting larger clinical trials to evaluate the efficacy of metabolic modulators like trimetazidine in ALS patients.

SUMO (Small Ubiquitin-like Modifier) proteins are a family of small proteins that are attached to and detached from other proteins in cells to modify their function. This process is called SUMOylation. SUMOylation is to signal to other cellular mechanisms that the protein attached must be processed. There are at least 4 SUMO isoforms in humans; SUMO-1, SUMO-2, SUMO-3, and SUMO-4. SUMO proteins are involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. enter image description here Transactive response DNA-binding protein 43 (TDP-43) is a nuclear RNA binding protein (RBP) involved in RNA metabolism. TDP-43 has a high propensity to aggregate because of its low solubility in cells and in vitro. The aggregation propensity of TDP-43 is increased by ALS/FTD-linked mutations and upon exposure to stress and has been observed in patients with C9orf72 hexanucleotide repeat expansion, the most common genetic cause of sporadic and familial.

Stress conditions trigger the accumulation of TDP-43 in cytosolic stress granules. The role of stress granules in modulating TDP-43 aggregation is ambiguous. Functionally, SUMO2/3-ylation has been shown to maintain stress granules in a dynamic state: SUMOylation inhibition impairs stress granule disassembly, but the underlying mechanism is still unknown.

In this paper, the authors report that upon oxidative stress (induced by sodium arsenite), TDP-43 becomes modified by SUMO2/3 protein chains and moves from the nucleus to cytoplasmic stress granules. This conclusion is probably also valid for other stress conditions, so this study is of great interest. When researchers blocked SUMOylation, TDP-43 became less mobile within the cell, stress granules took longer to disassemble, and TDP-43 was more likely to form insoluble aggregates. Yet this is not a study on humans, the authors used various immortal cell lines, motor neuron cells, and Caenorhabditis elegans worms. Furthermore, the authors used genetic therapies to infect cells to express or repress PIAS4. This is easy to do in vitro but most probably hard to achieve in a seriously ill patient.

Because TDP-43 aggregation is central to familial and sporadic ALS, approaches aimed at preventing TDP-43 aggregation hold promise for future treatments. How cells control TDP-43 aggregation is poorly understood. Modifiers of TDP-43 solubility include molecular chaperones and posttranslational modifications. Besides ubiquitination, which is a key posttranslational modification required to clear aggregation-prone proteins, phosphorylation of TDP-43 is emerging as a protective response to counteract its misfolding. Phosphorylation of TDP-43 decreases its assembly into condensates and suppresses TDP-43 aggregation and toxicity.

Under normal growth conditions, cells prefer to modify proteins with SUMO1, while during cellular stress, SUMO2 and SUMO3 are usually conjugated in the form of SUMO2/3 chains (referred to as SUMO2/3-ylation). TDP-43 when SUMO1-ylated stays in the nucleus, does not aggregate in the cytoplasm, and its splicing activity is modified.

Using experiments in cells, the authors show that conjugation of TDP-43 with SUMO2/3 coincides with stress granule assembly. Pharmacological inhibition of TDP-43 SUMO2/3-ylation triggers TDP-43 aggregation inside stress granules.

E3 SUMO-protein ligase PIAS4 is one of several protein inhibitors of activated STAT (PIAS) proteins. PIAS proteins act as transcriptional co-regulators with at least 60 different proteins to either activate or repress transcription. The transcription factors STAT, NF-κB, p73, and p53 are among the many proteins that PIAS interacts with. PIAS4 has been shown to recruit proteins to the site of the DNA damage and promote repair.

The authors found that PIAS4 helps attach SUMO2/3 to TDP-43. - PIAS4-mediated SUMO2/3-ylation increases the solubility of TDP-43 and prevents its aggregation in the cytoplasm. - Depleting PIAS4 leads to TDP-43 aggregation In motor neurons from the human spinal cord in familial ALS cases with TDP-43 and C9orf72 mutations, reduced cytoplasmic PIAS4 correlates with increased TDP-43 aggregates.

RNA binding appears to compete with SUMOylation: When cells are not subjected to stress, TDP-43 is mainly localized inside the nucleus, binding with high affinity to RNA. When TDP-43 is bound to RNA, it's less likely to be SUMOylated. When cellular RNA levels are low, there's increased SUMO2/3 modification This suggests SUMOylation may be a protective mechanism when TDP-43 isn't bound to RNA

The authors conclude that modification with SUMO2/3 chains maintains the solubility of RNA-free TDP-43 during stress.

There are many studies on reducing TDP-43 aggregates in ALS, but this one looks much more sophisticated than the previous ones. Yet this is mostly an in-vitro study. Long pre-clinical studies must be conducted on mammals to verify if a simple and safe agonist of PIAS4 (which does not exist today) could improve the health of ALS patients.


Please, help us continue to provide valuable information: